Skip to main content

Syndax Pharmaceuticals Inc

SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001395937

In the last 90 days, Syndax Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 242 institutions reported holding it in 13F filings for Q2 2026, worth $2.36B in total; no superinvestor holds it.

Holders of 5% or more of SNDX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Syndax Pharmaceuticals Inc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of SNDX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Kynam Capital Management, LP13G/A9.98%8.52M shares–Feb 14, 20251 filingFeb 14, 2025SEC
BlackRock, Inc.13G/A7.80%6.74M shares–Apr 17, 20251 filingApr 17, 2025SEC
Goldman Sachs Group Inc13G/A6.50%5.58M shares+1.30 ppfrom 5.20%Feb 12, 20253 filingsAug 13, 2025SEC
State Street Corp13G5.30%4.60M sharesNewFeb 9, 20261 filingFeb 9, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

15 Schedule 13D and 13G filings on Syndax Pharmaceuticals Inc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on SNDX
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 15, 20264:18 PM ETPoint72 Asset Management, L.P.and 2 others13G/A2.30%1.99M shares−2.70 ppfrom 5.00%Below 5%Mar 31, 2026SEC
Mar 27, 20261:15 PM ETVanguard Group Inc13G/A0.00%0 shares−7.16 ppfrom 7.16%Below 5%Mar 13, 2026SEC
Feb 9, 20268:08 AM ETState Street Corp13G5.30%4.60M sharesNewDec 31, 2025SEC
Jan 30, 20262:43 PM ETVanguard Group Inc13G/A7.16%6.23M shares–Dec 31, 2025SEC
Aug 18, 20254:53 PM ETPoint72 Asset Management, L.P.and 2 others13G5.00%4.33M shares+2.30 ppfrom 2.70%Aug 15, 2025SEC
Aug 14, 20255:39 PM ETPoint72 Asset Management, L.P.and 2 others13G/A2.70%2.31M shares−2.30 ppfrom 5.00%Below 5%Jun 30, 2025SEC
Aug 13, 20255:52 PM ETGoldman Sachs Group Incand 1 other13G/A6.50%5.58M shares+1.30 ppfrom 5.20%Jun 30, 2025SEC
May 9, 202512:34 PM ETGoldman Sachs Group Incand 1 other13G/A5.20%4.51M shares−1.80 ppfrom 7.00%Mar 31, 2025SEC
May 7, 202511:25 AM ETMorgan Stanleyand 1 other13G/A2.40%2.04M shares−3.90 ppfrom 6.30%Below 5%Mar 31, 2025SEC
Apr 17, 20259:35 AM ETBlackRock, Inc.13G/A7.80%6.74M shares–Mar 31, 2025SEC
Mar 7, 202511:13 AM ETWellington Management Group LLPand 2 others13G/A0.00%35.7K shares–Below 5%Feb 28, 2025SEC
Feb 14, 20255:18 PM ETKynam Capital Management, LPand 2 others13G/A9.98%8.52M shares–Dec 31, 2024SEC
Feb 12, 202511:39 AM ETGoldman Sachs Group Incand 1 other13G7.00%5.95M sharesNewDec 31, 2024SEC
Feb 5, 202510:03 AM ETMorgan Stanleyand 1 other13G6.30%5.36M sharesNewDec 31, 2024SEC
Jan 22, 20255:50 PM ETPoint72 Asset Management, L.P.and 2 others13G5.00%4.28M sharesNewJan 21, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Syndax Pharmaceuticals Inc shares.

No Form 144 notices for Syndax Pharmaceuticals Inc are on file.